

Caldolor® (ibuprofen) – Expanded indication

- On May 11, 2023, the FDA approved Cumberland Pharmaceuticals' <u>Caldolor (ibuprofen)</u> injection, in adults and pediatric patients aged 3 months and older for the:
 - Management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics
 - Reduction of fever.
- Caldolor was previously approved for these indications in patients aged 6 months and older.
- Caldolor carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.
- The recommended dose of Caldolor for pediatric patients ages 3 months to less than 6 months is a single dose at 10 mg/kg intravenously up to a maximum single dose of 100 mg. Infusion time must be at least 10 minutes.
 - Refer to the Caldolor drug label for dosing for older patients.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.